Condition: Biphenotypic Acute Leukemia · Acute Lymphoblastic Leukemia · Myeloblastic Leukemia · Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
This description comes directly from the study's public registry record.
Maschan Michael,, MD, PhD · +79166512145 · mmaschan@yandex.ru
Always discuss trial participation with your own doctor first.
| National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756152